[1]
|
Zhang, H. and Barratt, J. (2021) Is IgA Nephropathy the Same Disease in Different Parts of the World? Seminars in Immunopathology, 43, 707-715. https://doi.org/10.1007/s00281-021-00884-7
|
[2]
|
Schena, F.P. and Nistor, I. (2018) Epidemiology of IgA Nephropathy: A Global Perspective. Seminars in Nephrology, 38, 435-442. https://doi.org/10.1016/j.semnephrol.2018.05.013
|
[3]
|
Waldherr, R., Rambausek, M., Duncker, W.D. and Ritz, E. (1989) Frequency of Mesangial IgA Deposits in a Non-Selected Autopsy Series. Nephrology, Dialysis, Transplantation, 4, 943-946. https://doi.org/10.1093/ndt/4.11.943
|
[4]
|
Rajasekaran, A., Julian, B.A. and Rizk, D.V. (2021) IgA Nephropathy: An Interesting Autoimmune Kidney Disease. The American Journal of the Medical Sciences, 361, 176-194. https://doi.org/10.1016/j.amjms.2020.10.003
|
[5]
|
Rovin, B., Adler, S., Barratt, J., Bridoux, F., Burdge, K., Chan, D., et al. (2021) Executive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 100, 753-779.
https://doi.org/10.1016/j.kint.2021.05.015
|
[6]
|
Suzuki, H., Kiryluk, K., Novak, J., Moldoveanu, Z., Herr, A.B., Renfrow, M.B., et al. (2011) The Pathophysiology of IgA Nephropathy. Journal of the American Society of Nephrology: JASN, 22, 1795-1803.
https://doi.org/10.1681/ASN.2011050464
|
[7]
|
Trimarchi, H., Barratt, J., Cattran, D.C., et al. (2017) Oxford Clas-sification of IgA Nephropathy 2016: An Update from the IgA Nephropathy Classification Working Group. Kidney In-ternational, 91, 1014-1021.
https://doi.org/10.1016/j.kint.2017.02.003
|
[8]
|
Prasad, N., Kumar, S., Manjunath, R., Bhadauria, D., et al. (2015) Real-Time Ultrasound-Guided Percutaneous Renal Biopsy with Needle Guide by Nephrologists Decreases Post-Biopsy Complications. Clinical Kidney Journal, 8, 151-156. https://doi.org/10.1093/ckj/sfv012
|
[9]
|
王雪, 刘亚, 孟巧云, 戴春. 血清IgA/C3值对IGA肾病的诊断价值[J]. 山东医药, 2021, 61(34): 83-86.
|
[10]
|
黄勇, 黎才丽, 何玉叶. IgA/C3在IgA肾病中的诊断价值分析[J]. 国际检验医学杂志, 2018(1): 2290-2292.
|
[11]
|
谢伟基, 洪桂填, 薛茜, 林智郡, 谢奕, 徐晓嫦, 等. 血清IgA/C3对IgA肾病诊断及治疗预后的意义[J]. 临床肾脏病杂志, 2019, 19(5): 311-316, 321.
|
[12]
|
Liu, L.L., Jiang, Y., Wang, L.N. and Liu, N. (2012) Urinary Mannose-Binding Lectin Is a Bi-omarker for Predicting the Progression of Immunoglobulin (Ig)A Nephropathy. Clinical and Experimental Immunology, 169, 148-155.
https://doi.org/10.1111/j.1365-2249.2012.04604.x
|
[13]
|
张纪浩, 刘佳, 杨开月, 牛洪琳. IgA肾病无创诊断方法研究进展[J]. 中国中西医结合肾病杂志, 2021, 22(7): 650-652.
|
[14]
|
Hu, Q., Zhang, W.J., Lin, Z.Q., Wang, X.Y., Zheng, H.Y., Wei, H.M. and He, H.G. (2019) Combined Acoustic Radiation Force Impulse and Conventional Ultra-sound in the Quantitative Assessment of Immunoglobulin a Nephropathy. Ultrasound in Medicine & Biology, 45, 2309-2316. https://doi.org/10.1016/j.ultrasmedbio.2019.05.013
|
[15]
|
Cheng, J., Zhang, X., Tian, J., Li, Q. and Chen, J. (2012) Combination Therapy an ACE Inhibitor and an Angiotensin Receptor Blocker for IgA Nephropathy: A Me-ta-Analysis. International Journal of Clinical Practice, 66, 917-923.
https://doi.org/10.1111/j.1742-1241.2012.02970.x
|
[16]
|
Ji, Y., Yang, K., Xiao, B., Lin, J., Zhao, Q., Bhuva, M.S. and Yang, H. (2019) Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blocker Therapy for IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Journal of Cellular Biochemistry, 120, 3689-3695. https://doi.org/10.1002/jcb.27648
|
[17]
|
Tian, L., Shao, X., Xie, Y., Wang, L., Wang, Q., Che, X., et al. (2015) The Long-Term Efficacy and Safety of Immunosuppressive Therapy on the Progression of IgA Nephropathy: A Meta-Analysis of Controlled Clinical Trials with More than 5-Year Follow-Up. Expert Opinion on Pharmacotherapy, 16, 1137-1147.
https://doi.org/10.1517/14656566.2015.1038238
|
[18]
|
Gao, R., Wu, W., Wen, Y. and Li, X. (2017) Hydroxychlo-roquine Alleviates Persistent Proteinuria in IgA Nephropathy. International Urology and Nephrology, 49, 1233-1241. https://doi.org/10.1007/s11255-017-1574-2
|
[19]
|
Fellström, B.C., Barratt, J., Cook, H., Coppo, R., Feehally, J., et al. (2017) Targeted-Release Budesonide versus Placebo in Patients with IgA Nephropathy (NEFIGAN): A Double-Blind, Randomised, Placebo-Controlled Phase 2b Trial. The Lancet (London, England), 389, 2117-2127. https://doi.org/10.1016/S0140-6736(17)30550-0
|
[20]
|
刘兴红, 戴欢子. IgA肾病精准治疗策略的探索[J]. 临床肾脏病杂志, 2022, 22(3): 253-258.
|
[21]
|
Yang, Y.Z., Chen, P., Liu, L.J., Cai, Q.Q., Shi, S.F., Chen, Y.Q., et al. (2019) Comparison of the Effects of Hydroxychloroquine and Corticosteroid Treatment on Proteinuria in IgA Nephropathy: A Case-Control Study. BMC Nephrology, 20, Article No. 297. https://doi.org/10.1186/s12882-019-1488-6
|
[22]
|
Yang, Y.-Z., et al. (2019) Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 74, 15-22. https://doi.org/10.1053/j.ajkd.2019.01.026
|
[23]
|
Xie, J., Lv, J., Wang, W., Li, G., Liu, Z., Chen, H., et al. (2018) Kidney Failure Risk Prediction Equations in IgA Nephropathy: A Mul-ticenter Risk Assessment Study in Chinese Patients. American Journal of Kidney Diseases, 72, 371-380. https://doi.org/10.1053/j.ajkd.2018.01.043
|
[24]
|
Barbour, S.J., Coppo, R., Zhang, H., Liu, Z.H., Suzuki, Y., et al. (2019) Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Internal Medicine, 179, 942-952. https://doi.org/10.1001/jamainternmed.2019.0600
|